- Conditions
- Pseudobulbar Affect (PBA)
- Interventions
- dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg, dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg, Placebo
- Drug
- Lead sponsor
- Avanir Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 326 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 45
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Anaheim, California + 39 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–4
of 4
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Central Neuropathic Pain, Multiple Sclerosis
- Interventions
- AVP-923-45, AVP-923-30, AVP-923-20, Placebo
- Drug
- Lead sponsor
- Avanir Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 209 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 44
- States / cities
- Cullman, Alabama • Phoenix, Arizona • Berkeley, California + 40 more
- Conditions
- Healthy
- Interventions
- Imlunestrant, Repaglinide, Omeprazole, Dextromethorphan, Quinidine, Rosuvastatin, Digoxin
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 113 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 3
- States / cities
- Cypress, California • South Miami, Florida • San Antonio, Texas
- Conditions
- Agitation, Alzheimer's Disease
- Interventions
- AVP-923-20, Placebo, AVP-923-30
- Drug
- Lead sponsor
- Avanir Pharmaceuticals
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 44
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Fresno, California + 36 more